GlassScriptPhysician profile
Robert A Mckinley
NPI 1053425637
$10,936.34
in general payments reported to CMS, 2019-2025
44 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,419 · 2020: $694 · 2021: $876 · 2022: $2,650 · 2023: $1,856 · 2024: $2,063 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,217 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,217.45 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,914.71 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,856.07 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Grifols USA, LLC | $841.95 | 2019-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $518.09 | 2019-2025 | Tyvaso, Tyvaso |
| Insmed, INC. | $492.93 | 2019-2025 | Brinsupri, Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.50 | 2019-2025 | Ofev, Stiolto Respimat |
| Pulmonx Corporation | $412.90 | 2022-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Regeneron Healthcare Solutions, INC. | $409.36 | 2022-2024 | Dupixent |
| Mylan Specialty L.P. | $400.84 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $400.17 | 2021-2025 | Glassia |
| Genzyme Corporation | $365.81 | 2021-2025 | |
| Inspire Medical Systems, INC. | $347.71 | 2024-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $304.15 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $222.53 | 2019-2023 | Xarelto |
| Tetraphase Pharmaceuticals, INC. | $206.23 | 2019-2020 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $178.00 | 2019-2023 | Xolair |
| Verona Pharma, INC. | $170.66 | 2025 | Ohtuvayre |
| La Jolla Pharmaceutical Company | $160.09 | 2021-2025 | Xerava, Giapreza |
| Novartis Pharmaceuticals Corporation | $142.01 | 2019-2023 | |
| Amgen INC. | $131.50 | 2021-2022 | |
| Baxter Healthcare | $119.11 | 2022-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Viatris Specialty LLC | $109.50 | 2025 | Yupelri |
| Abbvie INC. | $107.25 | 2022-2025 | |
| Electromed, INC. | $77.27 | 2019-2024 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $75.15 | 2022 | |
| Sanofi-Aventis U.S. LLC | $57.99 | 2022 | |
| Shionogi INC | $52.67 | 2022 | |
| Resmed Corp | $51.36 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $51.24 | 2019-2023 | Recarbrio, Zerbaxa, Dificid |
| Ambu INC. | $34.00 | 2022 | |
| Pfizer INC. | $32.48 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $31.95 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $31.14 | 2022 | |
| Olympus America INC. | $29.99 | 2020-2022 | |
| Gilead Sciences, INC. | $24.86 | 2019 | |
| Medtronic, INC. | $23.74 | 2023 | Illumisite |
| Bayer Healthcare Pharmaceuticals INC. | $22.60 | 2022 | |
| Circassia INC. | $17.70 | 2019 | |
| Abiomed | $16.33 | 2020 | |
| Shire North American Group INC | $15.81 | 2019 | |
| Inogen, INC. | $15.78 | 2024 | |
| Philips North America LLC | $15.32 | 2019 | |
| Zoll Respicardia, INC. | $13.66 | 2025 | Remede System |
| Allergan, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mckinley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.